Correction of glutathione deficiency in the lower respirat-ory tract of HIV seropositive individuals by glutathione aerosol treatment

K. J. Holroyd, R. Buhl, Z. Borok, J. H. Roum, D. Czerski, Ronald Crystal, A. D. Bokser, G. J. Grimes, A. M. Cantn

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Background-Concentrations of glutathione, a ubiquitous tripeptide with immune enhancing and antioxidant properties, are decreased in the blood and lung epithelial lining fluid of human immunodeficiency virus (HIV) seropositive individuals. Since the lung is the most common site of infection in those who progress to AIDS it is rational to consider whether it is possible to safely augment glutathione levels in the epithelial lining fluid of HIV seropositive individuals, thus potentially improving local host defence. Methods-Purified reduced glutathione was delivered by aerosol to HIV seropositive individuals (n = 14) and the glutathione levels in lung epithelial lining fluid were compared before and at one, two, and three hours after aerosol administration. Results-Before treatment total glutathione concentrations in the epithelial lining fluid were approximately 60% of controls. After three days of twice daily doses each of 600 mg reduced glutathione, total glutathione levels in the epithelial lining fluid increased and remained in the normal range for at least three hours after treatment. Strikingly, even though >95% of the glutathione in the aerosol was in its reduced form, the percentage of oxidised glutathione in epithelial lining fluid increased from 5% before treatment to about 400/o three hours after treatment, probably reflecting the use of glutathione as an antioxidant in vivo. No adverse effects were observed. Conclusions-It is feasible and safe to use aerosolised reduced glutathione to augment the deficient glutathione levels of the lower respiratory tract of HIV seropositive individuals. It is rational to evaluate further the efficacy of this tripeptide in improving host defence in HIV seropositive individuals.

Original languageEnglish
Pages (from-to)985-989
Number of pages5
JournalThorax
Volume48
Issue number10
DOIs
Publication statusPublished - 1 Jan 1993
Externally publishedYes

Fingerprint

Aerosols
Glutathione
HIV
Lung
Antioxidants
Glutathione Disulfide
Respiratory System
Reference Values
Acquired Immunodeficiency Syndrome

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Correction of glutathione deficiency in the lower respirat-ory tract of HIV seropositive individuals by glutathione aerosol treatment. / Holroyd, K. J.; Buhl, R.; Borok, Z.; Roum, J. H.; Czerski, D.; Crystal, Ronald; Bokser, A. D.; Grimes, G. J.; Cantn, A. M.

In: Thorax, Vol. 48, No. 10, 01.01.1993, p. 985-989.

Research output: Contribution to journalArticle

Holroyd, KJ, Buhl, R, Borok, Z, Roum, JH, Czerski, D, Crystal, R, Bokser, AD, Grimes, GJ & Cantn, AM 1993, 'Correction of glutathione deficiency in the lower respirat-ory tract of HIV seropositive individuals by glutathione aerosol treatment', Thorax, vol. 48, no. 10, pp. 985-989. https://doi.org/10.1136/thx.48.10.985
Holroyd, K. J. ; Buhl, R. ; Borok, Z. ; Roum, J. H. ; Czerski, D. ; Crystal, Ronald ; Bokser, A. D. ; Grimes, G. J. ; Cantn, A. M. / Correction of glutathione deficiency in the lower respirat-ory tract of HIV seropositive individuals by glutathione aerosol treatment. In: Thorax. 1993 ; Vol. 48, No. 10. pp. 985-989.
@article{652e7fca43184936aa207bd6ce1ac727,
title = "Correction of glutathione deficiency in the lower respirat-ory tract of HIV seropositive individuals by glutathione aerosol treatment",
abstract = "Background-Concentrations of glutathione, a ubiquitous tripeptide with immune enhancing and antioxidant properties, are decreased in the blood and lung epithelial lining fluid of human immunodeficiency virus (HIV) seropositive individuals. Since the lung is the most common site of infection in those who progress to AIDS it is rational to consider whether it is possible to safely augment glutathione levels in the epithelial lining fluid of HIV seropositive individuals, thus potentially improving local host defence. Methods-Purified reduced glutathione was delivered by aerosol to HIV seropositive individuals (n = 14) and the glutathione levels in lung epithelial lining fluid were compared before and at one, two, and three hours after aerosol administration. Results-Before treatment total glutathione concentrations in the epithelial lining fluid were approximately 60{\%} of controls. After three days of twice daily doses each of 600 mg reduced glutathione, total glutathione levels in the epithelial lining fluid increased and remained in the normal range for at least three hours after treatment. Strikingly, even though >95{\%} of the glutathione in the aerosol was in its reduced form, the percentage of oxidised glutathione in epithelial lining fluid increased from 5{\%} before treatment to about 400/o three hours after treatment, probably reflecting the use of glutathione as an antioxidant in vivo. No adverse effects were observed. Conclusions-It is feasible and safe to use aerosolised reduced glutathione to augment the deficient glutathione levels of the lower respiratory tract of HIV seropositive individuals. It is rational to evaluate further the efficacy of this tripeptide in improving host defence in HIV seropositive individuals.",
author = "Holroyd, {K. J.} and R. Buhl and Z. Borok and Roum, {J. H.} and D. Czerski and Ronald Crystal and Bokser, {A. D.} and Grimes, {G. J.} and Cantn, {A. M.}",
year = "1993",
month = "1",
day = "1",
doi = "10.1136/thx.48.10.985",
language = "English",
volume = "48",
pages = "985--989",
journal = "Thorax",
issn = "0040-6376",
publisher = "BMJ Publishing Group",
number = "10",

}

TY - JOUR

T1 - Correction of glutathione deficiency in the lower respirat-ory tract of HIV seropositive individuals by glutathione aerosol treatment

AU - Holroyd, K. J.

AU - Buhl, R.

AU - Borok, Z.

AU - Roum, J. H.

AU - Czerski, D.

AU - Crystal, Ronald

AU - Bokser, A. D.

AU - Grimes, G. J.

AU - Cantn, A. M.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Background-Concentrations of glutathione, a ubiquitous tripeptide with immune enhancing and antioxidant properties, are decreased in the blood and lung epithelial lining fluid of human immunodeficiency virus (HIV) seropositive individuals. Since the lung is the most common site of infection in those who progress to AIDS it is rational to consider whether it is possible to safely augment glutathione levels in the epithelial lining fluid of HIV seropositive individuals, thus potentially improving local host defence. Methods-Purified reduced glutathione was delivered by aerosol to HIV seropositive individuals (n = 14) and the glutathione levels in lung epithelial lining fluid were compared before and at one, two, and three hours after aerosol administration. Results-Before treatment total glutathione concentrations in the epithelial lining fluid were approximately 60% of controls. After three days of twice daily doses each of 600 mg reduced glutathione, total glutathione levels in the epithelial lining fluid increased and remained in the normal range for at least three hours after treatment. Strikingly, even though >95% of the glutathione in the aerosol was in its reduced form, the percentage of oxidised glutathione in epithelial lining fluid increased from 5% before treatment to about 400/o three hours after treatment, probably reflecting the use of glutathione as an antioxidant in vivo. No adverse effects were observed. Conclusions-It is feasible and safe to use aerosolised reduced glutathione to augment the deficient glutathione levels of the lower respiratory tract of HIV seropositive individuals. It is rational to evaluate further the efficacy of this tripeptide in improving host defence in HIV seropositive individuals.

AB - Background-Concentrations of glutathione, a ubiquitous tripeptide with immune enhancing and antioxidant properties, are decreased in the blood and lung epithelial lining fluid of human immunodeficiency virus (HIV) seropositive individuals. Since the lung is the most common site of infection in those who progress to AIDS it is rational to consider whether it is possible to safely augment glutathione levels in the epithelial lining fluid of HIV seropositive individuals, thus potentially improving local host defence. Methods-Purified reduced glutathione was delivered by aerosol to HIV seropositive individuals (n = 14) and the glutathione levels in lung epithelial lining fluid were compared before and at one, two, and three hours after aerosol administration. Results-Before treatment total glutathione concentrations in the epithelial lining fluid were approximately 60% of controls. After three days of twice daily doses each of 600 mg reduced glutathione, total glutathione levels in the epithelial lining fluid increased and remained in the normal range for at least three hours after treatment. Strikingly, even though >95% of the glutathione in the aerosol was in its reduced form, the percentage of oxidised glutathione in epithelial lining fluid increased from 5% before treatment to about 400/o three hours after treatment, probably reflecting the use of glutathione as an antioxidant in vivo. No adverse effects were observed. Conclusions-It is feasible and safe to use aerosolised reduced glutathione to augment the deficient glutathione levels of the lower respiratory tract of HIV seropositive individuals. It is rational to evaluate further the efficacy of this tripeptide in improving host defence in HIV seropositive individuals.

UR - http://www.scopus.com/inward/record.url?scp=0027486588&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027486588&partnerID=8YFLogxK

U2 - 10.1136/thx.48.10.985

DO - 10.1136/thx.48.10.985

M3 - Article

VL - 48

SP - 985

EP - 989

JO - Thorax

JF - Thorax

SN - 0040-6376

IS - 10

ER -